Celldex Book Value Per Share from 2010 to 2024

CLDX Stock

USD 26.76 1.38 4.90%

Celldex Therapeutics Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share will likely drop to 8.42 in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Celldex Therapeutics according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

8.85820141

Current Value

8.42

Quarterly Volatility

25.9063589

Credit Downgrade

Yuan Drop

Covid

Check Celldex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celldex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 5.8 M or Selling General Administrative of 29.4 M, as well as many indicators such as Price To Sales Ratio of 293, Dividend Yield of 0.0 or PTB Ratio of 3.62. Celldex financial statements analysis is a perfect complement when working with Celldex Therapeutics Valuation or Volatility modules.

Check out the analysis of Celldex Therapeutics Correlation against competitors.

For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

Latest Celldex Therapeutics' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Celldex Therapeutics over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Celldex Therapeutics' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Celldex Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 11.85 X

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Celldex Book Value Per Share Regression Statistics

	Arithmetic Mean	17.53
	Coefficient Of Variation	147.76
	Mean Deviation	18.07
	Median	11.88
	Standard Deviation	25.91
	Sample Variance	671.14
	Range	115
	R-Value	(0.09)
	Mean Square Error	717.23
	R-Squared	0.01
	Significance	0.76
	Slope	(0.51)
	Total Sum of Squares	9,396

Celldex Book Value Per Share History

	2024	8.42
	2023	8.86
	2022	6.96
	2021	9.78
	2020	7.06
	2019	6.48
	2018	11.88

Other Fundumenentals of Celldex Therapeutics

Tangible Book Value Per Share

Celldex Therapeutics Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Net Receivables	Accounts Payable	Short Term Debt	Common Stock	Intangible Assets	Current Deferred Revenue	Property Plant Equipment	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.98	-0.43	-0.67	0.33	0.94	0.36	0.73	0.03	0.39	0.19	0.54	0.44	0.88	0.84	-0.64	0.68	0.56	0.66	-0.53	0.67	0.61
Total Stockholder Equity	0.98		-0.43	-0.69	0.16	0.98	0.31	0.75	-0.07	0.27	0.03	0.5	0.32	0.93	0.91	-0.61	0.7	0.49	0.71	-0.57	0.74	0.69
Net Debt	-0.43	-0.43		-0.07	-0.09	-0.42	0.03	-0.23	0.13	-0.39	0.03	-0.55	-0.42	-0.15	-0.26	0.36	-0.04	0.09	-0.08	-0.03	0.02	0.07
Retained Earnings	-0.67	-0.69	-0.07		-0.06	-0.66	-0.6	-0.56	0.13	0.22	-0.08	0.06	0.11	-0.72	-0.66	0.64	-0.93	-0.76	-0.36	0.5	-0.64	-0.8
Total Liab	0.33	0.16	-0.09	-0.06		0.0	0.28	0.04	0.53	0.72	0.91	0.35	0.74	-0.05	-0.17	-0.31	0.11	0.48	-0.06	0.13	-0.19	-0.27
Total Current Assets	0.94	0.98	-0.42	-0.66	0.0		0.26	0.75	-0.17	0.16	-0.11	0.48	0.23	0.96	0.96	-0.55	0.66	0.38	0.73	-0.6	0.78	0.73
Net Receivables	0.36	0.31	0.03	-0.6	0.28	0.26		0.33	0.08	-0.02	0.29	-0.28	0.01	0.28	0.15	-0.4	0.45	0.67	-0.09	-0.55	0.09	0.23
Accounts Payable	0.73	0.75	-0.23	-0.56	0.04	0.75	0.33		-0.24	0.2	-0.06	0.34	0.21	0.74	0.68	-0.42	0.49	0.31	0.51	-0.68	0.53	0.56
Short Term Debt	0.03	-0.07	0.13	0.13	0.53	-0.17	0.08	-0.24		0.39	0.36	0.28	0.54	-0.19	-0.25	-0.02	-0.15	0.23	-0.03	0.16	-0.17	-0.3
Common Stock	0.39	0.27	-0.39	0.22	0.72	0.16	-0.02	0.2	0.39		0.45	0.68	0.79	0.05	0.01	-0.2	-0.14	0.22	0.15	0.04	-0.15	-0.31
Intangible Assets	0.19	0.03	0.03	-0.08	0.91	-0.11	0.29	-0.06	0.36	0.45		0.08	0.54	-0.13	-0.26	-0.22	0.08	0.37	-0.19	0.13	-0.24	-0.25
Current Deferred Revenue	0.54	0.5	-0.55	0.06	0.35	0.48	-0.28	0.34	0.28	0.68	0.08		0.81	0.33	0.39	-0.38	0.04	-0.01	0.3	0.04	0.09	-0.05
Property Plant Equipment	0.44	0.32	-0.42	0.11	0.74	0.23	0.01	0.21	0.54	0.79	0.54	0.81		0.09	0.07	-0.29	-0.05	0.12	0.07	0.13	-0.14	-0.27
Short Term Investments	0.88	0.93	-0.15	-0.72	-0.05	0.96	0.28	0.74	-0.19	0.05	-0.13	0.33	0.09		0.97	-0.47	0.7	0.42	0.79	-0.67	0.86	0.82
Net Tangible Assets	0.84	0.91	-0.26	-0.66	-0.17	0.96	0.15	0.68	-0.25	0.01	-0.26	0.39	0.07	0.97		-0.47	0.68	0.33	0.77	-0.54	0.85	0.8
Long Term Debt Total	-0.64	-0.61	0.36	0.64	-0.31	-0.55	-0.4	-0.42	-0.02	-0.2	-0.22	-0.38	-0.29	-0.47	-0.47		-0.66	-0.52	-0.14	0.16	-0.27	-0.34
Capital Surpluse	0.68	0.7	-0.04	-0.93	0.11	0.66	0.45	0.49	-0.15	-0.14	0.08	0.04	-0.05	0.7	0.68	-0.66		0.72	0.48	-0.25	0.73	0.8
Short Long Term Debt	0.56	0.49	0.09	-0.76	0.48	0.38	0.67	0.31	0.23	0.22	0.37	-0.01	0.12	0.42	0.33	-0.52	0.72		0.17	-0.31	0.32	0.41
Net Invested Capital	0.66	0.71	-0.08	-0.36	-0.06	0.73	-0.09	0.51	-0.03	0.15	-0.19	0.3	0.07	0.79	0.77	-0.14	0.48	0.17		-0.36	0.92	0.73
Long Term Investments	-0.53	-0.57	-0.03	0.5	0.13	-0.6	-0.55	-0.68	0.16	0.04	0.13	0.04	0.13	-0.67	-0.54	0.16	-0.25	-0.31	-0.36		-0.42	-0.5
Net Working Capital	0.67	0.74	0.02	-0.64	-0.19	0.78	0.09	0.53	-0.17	-0.15	-0.24	0.09	-0.14	0.86	0.85	-0.27	0.73	0.32	0.92	-0.42		0.92
Capital Stock	0.61	0.69	0.07	-0.8	-0.27	0.73	0.23	0.56	-0.3	-0.31	-0.25	-0.05	-0.27	0.82	0.8	-0.34	0.8	0.41	0.73	-0.5	0.92

Click cells to compare fundamentals

About Celldex Therapeutics Financial Statements

Celldex Therapeutics investors use historical fundamental indicators, such as Celldex Therapeutics' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Celldex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	8.86	8.42
Tangible Book Value Per Share	8.30	7.88

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC